

# Alice Tseng

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5497197/alice-tseng-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

36  
papers

626  
citations

14  
h-index

24  
g-index

37  
ext. papers

756  
ext. citations

3.4  
avg, IF

4.05  
L-index

#	Paper	IF	Citations
36	The intersection of drug interactions and adverse reactions in contemporary antiretroviral therapy. <i>Current Opinion in HIV and AIDS</i> , <b>2021</b> , 16, 292-302	4.2	2
35	An update on neuropsychiatric adverse effects with second-generation integrase inhibitors and nonnucleoside reverse transcriptase inhibitors. <i>Current Opinion in HIV and AIDS</i> , <b>2021</b> , 16, 309-320	4.2	3
34	Polypharmacy-associated risk of hospitalisation among people ageing with and without HIV: an observational study. <i>The Lancet Healthy Longevity</i> , <b>2021</b> , 2, e639-e650	9.5	2
33	Drug Interactions with Gender-Affirming Hormone Therapy: Focus on Antiretrovirals and Direct Acting Antivirals. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2020</b> , 16, 565-582	5.5	4
32	Therapeutic drug monitoring in treatment-experienced HIV-infected patients receiving darunavir-based salvage regimens: A case series. <i>Antiviral Research</i> , <b>2018</b> , 152, 111-116	10.8	5
31	Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences. <i>Annals of Pharmacotherapy</i> , <b>2017</b> , 51, 1008-1022	2.9	66
30	CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , <b>2016</b> , 2016, 4385643	2.6	14
29	Critical Review: Review of the Efficacy, Safety, and Pharmacokinetics of Raltegravir in Pregnancy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2016</b> , 72, 153-61	3.1	13
28	Drug interactions between antiretrovirals and drugs used to treat benign prostatic hyperplasia/lower urinary tract symptoms. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2016</b> , 12, 1211-24	5.5	4
27	Hepatotoxicity and potential drug interaction with ledipasvir/sofosbuvir in HIV/HCV infected patients. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 651-3	13.4	5
26	Drug-Drug Interactions With Antiviral Agents in People Who Inject Drugs Requiring Substitution Therapy. <i>Annals of Pharmacotherapy</i> , <b>2015</b> , 49, 796-807	2.9	17
25	The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future. <i>British Journal of Clinical Pharmacology</i> , <b>2015</b> , 79, 182-94	3.8	50
24	Development of a collaborative professional group for HIV pharmacists: experience from the Canadian HIV/AIDS Pharmacists Network. <i>International Journal of Pharmacy Practice</i> , <b>2015</b> , 23, 232-3	1.7	1
23	Managing drug interactions in HIV-infected adults with comorbid illness. <i>Cmaj</i> , <b>2015</b> , 187, 36-43	3.5	27
22	CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Updated Canadian guidelines for the treatment of hepatitis C infection in HIV-hepatitis C coinfecting adults. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , <b>2014</b> , 25, 311-20	2.6	6
21	Psychiatric treatment considerations with direct acting antivirals in hepatitis C. <i>BMC Gastroenterology</i> , <b>2013</b> , 13, 86	3	14
20	Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients. <i>Annals of Pharmacotherapy</i> , <b>2013</b> , 47, 1429-39	2.9	73

19	Drug interactions between antiretrovirals and hormonal contraceptives. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2013</b> , 9, 559-72	5.5	46
18	Safety and efficacy of CHOP for treatment of diffuse large B-cell lymphoma with different combination antiretroviral therapy regimens: SCULPT study. <i>Antiviral Therapy</i> , <b>2013</b> , 18, 699-707	1.6	6
17	CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , <b>2013</b> , 24, 217-38	2.6	9
16	Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs. <i>Current Infectious Disease Reports</i> , <b>2012</b> , 14, 67-82	3.9	39
15	Short communication: effects of age on virologic suppression and CD4 cell response in HIV-positive patients initiating combination antiretroviral therapy. <i>AIDS Research and Human Retroviruses</i> , <b>2012</b> , 28, 1579-83	1.6	9
14	Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines. <i>Canadian Journal of Hospital Pharmacy</i> , <b>2012</b> , 65, 125-45	0.5	29
13	Handbook and website on HIV drug therapy. <i>American Journal of Health-System Pharmacy</i> , <b>2012</b> , 69, 1284, 1286	2.2	2
12	Profile of etravirine for the treatment of HIV infection. <i>Therapeutics and Clinical Risk Management</i> , <b>2010</b> , 6, 49-58	2.9	8
11	Interactions between antifungal and antiretroviral agents. <i>Expert Opinion on Drug Safety</i> , <b>2010</b> , 9, 723-42	4.1	12
10	New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. <i>Expert Opinion on Pharmacotherapy</i> , <b>2009</b> , 10, 2445-66	4	59
9	Antiretroviral therapeutic drug monitoring in Canada: current status and recommendations for clinical practice. <i>Canadian Journal of Hospital Pharmacy</i> , <b>2009</b> , 62, 500-9	0.5	19
8	Advances in human immunodeficiency virus therapeutics. <i>Annals of Pharmacotherapy</i> , <b>2006</b> , 40, 704-9	2.9	5
7	Clinical impact of double protease inhibitor boosting with lopinavir/ritonavir and amprenavir as part of salvage antiretroviral therapy. <i>HIV Clinical Trials</i> , <b>2003</b> , 4, 301-10		11
6	Probable interaction between efavirenz and cyclosporine. <i>Aids</i> , <b>2002</b> , 16, 505-6	3.5	20
5	High rate of discontinuations of highly active antiretroviral therapy as a result of antiretroviral intolerance in clinical practice: missed opportunities for adherence support?. <i>Aids</i> , <b>2002</b> , 16, 1084-6	3.5	21
4	HIV pharmacy specialty residency program in Canada. <i>American Journal of Health-System Pharmacy</i> , <b>2001</b> , 58, 591-4	2.2	3
3	Comparative tolerability of therapies for cytomegalovirus retinitis. <i>Drug Safety</i> , <b>1999</b> , 21, 203-24	5.1	13
2	Development of an Interactive Computer-Assisted Program to Manage Medication Therapy in Hiv Infected Patients. <i>Drug Information Journal</i> , <b>1998</b> , 32, 649-656		1

- 1 The role of ganciclovir for the management of cytomegalovirus retinitis in HIV patients: Pharmacological review and update on new developments. *Canadian Journal of Infectious Diseases & Medical Microbiology*, **1996**, 7, 183-94